Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BioXcel Therapeutics, Inc. (BTAI : NSDQ)
 
 • Company Description   
BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States.

Number of Employees: 89

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.57 Daily Weekly Monthly
20 Day Moving Average: 569,121 shares
Shares Outstanding: 27.99 (millions)
Market Capitalization: $379.76 (millions)
Beta: 1.31
52 Week High: $39.00
52 Week Low: $9.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.80% 8.61%
12 Week -24.90% -15.60%
Year To Date -33.25% -18.45%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
555 LONG WHARF DRIVE
-
NEW HAVEN,CT 06511
USA
ph: 475-238-6837
fax: -
jmohite@theruthgroup.com http://www.bioxceltherapeutics.com
 
 • General Corporate Information   
Officers
Vimal Mehta - Chief Executive Officer and President
Peter Mueller - Chairman
Richard Steinhart - Chief Financial Officer
June Bray - Director
Sandeep Laumas - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09075P105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 27.99
Most Recent Split Date: (:1)
Beta: 1.31
Market Capitalization: $379.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.27 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.78 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.96
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -3.70%
vs. Previous Quarter: -20.43%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -48.25
12/31/21 - -46.42
09/30/21 - -44.97
ROA
03/31/22 - -45.13
12/31/21 - -43.54
09/30/21 - -42.33
Current Ratio
03/31/22 - 12.98
12/31/21 - 14.21
09/30/21 - 17.60
Quick Ratio
03/31/22 - 12.93
12/31/21 - 14.21
09/30/21 - 17.60
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.93
12/31/21 - 7.92
09/30/21 - 8.78
Inventory Turnover
03/31/22 - 0.00
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©